Search

everythinglearnresearchcommunity

for

Search:↓

Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.

The user is using oral minoxidil for hair loss and is considering trying Latisse on their hairline. They are also curious about the effects of latanoprost, caffeine, and melatonin topicals.

A user experienced issues with an order from Umbrella Labs, initially not receiving their product, PP405, and facing poor customer service, but eventually received the order after posting about it. Other users also reported similar problems with incomplete orders and lack of communication from the company.

A peptide-based hair loss treatment, PP405, reportedly increased hair density by 62% in 90 days, but these claims are unverified and met with skepticism. Users compared PP405 to Minoxidil and Finasteride, expressing doubts about its effectiveness without more evidence.

Pelage secured $120 million for PP405, a non-hormonal topical hair loss treatment, sparking debate on its potential as a breakthrough. Concerns about finasteride's side effects persist, with some suggesting alternatives like topical finasteride or dutasteride.

The conversation discusses purchasing experimental hair loss treatments KX-826, AHK-Cu, and PTD-DBM, with the user already using Minoxidil and having side effects from Finasteride. Concerns about the legitimacy of certain suppliers and the authenticity of products like pp405 are also mentioned.

The user started using pyrilutamide for hair loss on January 24, applying 1ml daily without other treatments, and after 10 days noticed reduced hair shedding and improved hair quality, with plans to continue for at least 6 months. They experienced chest pain initially, which could be related to starting methylphenidate or pyrilutamide, but the pain has since subsided.

The conversation is about the effectiveness of a hair loss treatment product containing 0.01% Latanoprost, with the user considering trying it as a vehicle for RU58841. The user questions whether the dosage is too low to be effective.

A user discusses a topical prescription for hair regrowth containing Minoxidil, Finasteride, and Latanoprost, noting Latanoprost's side effect of promoting eyelash and eyebrow growth. Others share experiences and information about Latanoprost, highlighting its origins as a glaucoma drug and potential side effects.

A 27-year-old experienced significant hair regrowth after a hair transplant with 4349 grafts, supported by minoxidil and finasteride, improving his confidence. He plans to update on further progress at 9–12 months.

Capilia Longa and Scandinavian Biolabs are discussed, with skepticism about their effectiveness and value. The conversation suggests avoiding these products due to high cost and perceived lack of results.

PP405 is considered a promising hair loss treatment, potentially replacing minoxidil but not finasteride. Users are hopeful for future treatments like GT20029 and VDPHL01, while remaining cautious about effectiveness and side effects.

A user shared their experience with a 7600 graft hair transplant using scalp, beard, and chest hair over three procedures, expressing satisfaction with the results despite mixed feedback. They also used finasteride to thicken hair and considered scalp micropigmentation for further improvement.

Hair loss treatments, including PP405, minoxidil, finasteride, and RU58841, with hopes for future solutions. Participants discuss the emotional impact of hair loss and consider alternatives like hair transplants or acceptance.

The user experienced significant hair regrowth and improved hair quality after six months of using oral minoxidil, finasteride, and micro-needling. They reported increased libido initially but no other side effects, and they plan to continue the treatment.

The conclusion of the conversation is that the user, djamezz, has experienced significant regrowth and improved density in their hairline by using treatments such as RU (RU58841), dut (dutasteride), and Inkey's Caffeine Scalp treatment. They are satisfied with their progress and do not plan to cut off their hair.

The user is seeking recommendations for a knowledgeable dermatologist in the Denver/Boulder area to address male pattern baldness, as they are dissatisfied with their current treatment of topical finasteride and are considering switching to dutasteride. They feel their current doctor is not open to exploring different treatments that could improve hairline thickness.

The conversation discusses the potential updates on the pp405 trial for hair loss, with completion expected by December 2025. Participants express skepticism about new treatments, suggesting continued use of finasteride, while others hope for innovative solutions beyond current medications.

People are discussing the use of an untested hair loss treatment called PP405, which is not available on the grey market. Some users are trying a mimic formulation called HP3, reporting thicker hair but no new growth yet.

A user shared their 6-month hair loss progress using topical minoxidil, oral finasteride, and microneedling, reporting positive results despite recent shedding. They also mentioned using rosemary oil and a special head lotion for dandruff.

A new hair loss treatment, pp405, may regrow hair better than finasteride and minoxidil, with potential availability by 2028. However, there is skepticism about its effectiveness and commercialization timeline.

The conversation discusses progress with a hair loss treatment regimen that includes once daily topical Finasteride, Pyrilutamide, and WAY-316606. Specific treatments for hair loss are being shared and discussed.

The user shared progress on hair regrowth using a topical minoxidil/finasteride spray, dermarolling weekly, and a product similar to pp405. They reported some regrowth with no side effects from the new product.

The clinic diagnosed the user with NW3 and AGA, noting thinning hair despite using finasteride for 3 years, and suggested PRP and Mesotherapy before considering a transplant. The user questions the necessity of these treatments without confirming retrograde alopecia and its treatability.

The conversation is about a user assessing their hair loss as Norwood 1.5 and discussing their use of oral minoxidil and finasteride for 2.5 years, which improved their hair density. They are content with their current progress but hope to reach Norwood 1.

The conversation is about a user sharing their positive experience with Scalp Micropigmentation (SMP) for hair loss, highlighting the natural look achieved by a specialized artist. The procedure cost $2600 and was done by Alex Corona in Panama City Beach, FL.

The conversation discusses a clinical trial for Setipiprant in the US, starting June 29th, with eligibility excluding recent users of minoxidil or finasteride. It encourages informed decision-making before signing up.

PP405 is a potential hair loss treatment that may reactivate dormant hair follicles, with Phase 3 trials expected. Some users are cautious, suggesting using finasteride in the meantime, while others are skeptical about PP405's effectiveness.

PP405 is ineffective for miniaturized, fibrosed hair follicles in androgenetic alopecia. AMP303 may activate hair follicle stem cells, but minoxidil and finasteride are still the main treatments.

The user is using a treatment of topical minoxidil 7% and finasteride 0.1% twice daily, along with a low-level laser therapy cap, biotin, and collagen supplements, and is seeing good progress on the hairline and temples but not the midscalp. They experienced initial shedding, saw results by month three, and are happy with the progress, though some users express concern about using finasteride at a young age.